Carcinoid syndrome staging

Carcinoid syndrome Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Carcinoid Syndrome from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Staging
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
Chest X Ray
CT
MRI
Echocardiography or Ultrasound
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Carcinoid syndrome staging On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Carcinoid syndrome staging All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Carcinoid syndrome staging
CDC on Carcinoid syndrome staging
Carcinoid syndrome staging in the news
Blogs on Carcinoid syndrome staging
Directions to Hospitals Treating Carcinoid syndrome
Risk calculators and risk factors for Carcinoid syndrome staging

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Parminder Dhingra, M.D. [2]

Staging

Definitions of TNM

Neuroendocrine Tumors: Stomach

• Primary Tumor (T)

• TX-Primary tumor cannot be assessed.

• T0-No evidence of primary tumor.

• Tis-Carcinoma in situ/dysplasia (tumor size <0.5 mm), confined to mucosa.

• T1-Tumor invades lamina propria or submucosa and ≤1 cm in size.

• T2-Tumor invades muscularis propria or >1 cm in size.

• T3-Tumor penetrates subserosa.

• T4-Tumor invades visceral peritoneum (serosal) or other organs or adjacent structures.

   For any T, add (m) for multiple tumors.